Memory loss, emotional fluctuations, and functioning impairments are frequent signs of Alzheimer's disease (AD). Dementia, which includes AD, affects 50 million people worldwide, the majority of whom are elderly. AD is the world's fifth biggest cause of mortality, according to the World Health Organization (WHO), with the number of fatalities expected to quadruple by 2050 if present trend continue. 1,2 Brain imaging, physical and cognitive examinations, laboratory testing, and medical history are used to diagnose AD. 3 Risk factors of the AD include apolipoprotein E4 (APOE4) genotype and traumatic brain injury, family history and age, obesity, diabetes, hypercholesterolemia, hypertension, and illiteracy. The most prevalent causes of AD are mutations in the genes producing the amyloid precursor protein (APP), presenilin 2 (PSEN2), and presenilin 1 (PSEN1). 4 As a result, both pharmaceutical and nonpharmacological therapies, such as physical, social, and cognitive activities, should be included in the treatment plan. Lithium and sodium valproate are two medicines used to treat mild to severe cognitive impairment. 5,6 Nonsteroidal anti-inflammatory medications (NSAIDs) like naproxen and ibuprofen are also used to treat neuroinflammation and prevent neurodegeneration. 7,8 Ganstigmine, metrifonate, lecithin, ibuprofen, rofecoxib, latrepiridine, omega-3 polyunsaturated fatty acids, vitamin B, and vitamin E are among the medications that have failed clinical studies. These drugs have been linked to headaches, nausea, vomiting, neuromuscular dysfunction, and respiratory problems. 5,9 Only five FDA-approved medications are now available to treat the symptoms of Alzheimer's disease. Aducanumab was just authorized for use in the year 2021. Memantine (N-methyl-D-aspartate receptor) has been on the market for 10 years (NMDAR antagonist). The remaining five medications are rivastigmine, donepezil (both cholinesterase inhibitors [ChEls]), memantine (an NMDAR antagonist), and galantamine (an NMDAR antagonist). 3,10 In recent years, stem cell therapy has exhibited significant progress in treating AD, as seen by multiple improvements in clinical studies. Self-generation, multiplication, division, and reprogramming for multi-lineage activities are among their many astonishing abilities. Consequently, they can be integrated into existing neural network topologies in this fashion.